Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme

Abstract Introduction Biosimilars have provided additional treatment options for patients with immune-mediated inflammatory diseases. This study evaluated the real-world use of adalimumab biosimilar ABP 501 in European patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic a...

Full description

Saved in:
Bibliographic Details
Main Authors: Ran Jin, James M. Haughton, Emily J. Goddard, Delphine Courmier, Waldemar Radziszewski, Rachael H. Meadows, James Piercy, Stanley Cohen
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-03-01
Series:Rheumatology and Therapy
Subjects:
Adalimumab
Ankylosing spondylitis
Biosimilar
Patient-reported outcomes
Psoriasis
Psoriatic arthritis
Online Access:https://doi.org/10.1007/s40744-025-00755-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40744-025-00755-9

Similar Items